DOCSLIB.ORG

Formulary 12 Edition

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Drug and Therapeutics Committee Formulary 12 th Edition Version14.3 July 2015 Compiled on behalf of the Drug and Therapeutics Committee by Eleanore Atkinson Medicines Information Pharmacist Formulary 12 th Edition [v14.3] Contents Introduction ..................................................................................................................................... 11 Purpose ............................................................................................................................................... 11 How to use this Formulary .................................................................................................................. 11 Prescribing Formulary drugs............................................................................................................... 11 Prescribing a non-Formulary drug ...................................................................................................... 11 Procedure for additions to and amendment of the Formulary ............................................................. 11 Prescribing information ....................................................................................................................... 12 Filling in prescription charts ............................................................................................................... 12 Intravenous antibiotics ........................................................................................................................ 12 Controlled drugs ................................................................................................................................. 12 Discharge prescriptions ...................................................................................................................... 12 Out-patient prescriptions .................................................................................................................... 13 Hospital staff prescriptions ................................................................................................................. 13 Policy for personal prescribing by medical staff ................................................................................. 13 Unlicensed medicines ......................................................................................................................... 14 Policy for the use of unlicensed medicinal products ........................................................................... 14 Ward stock .......................................................................................................................................... 15 Patients own drugs .............................................................................................................................. 15 Substitution ......................................................................................................................................... 15 Clinical trials....................................................................................................................................... 15 Pharmacy information ......................................................................................................................... 16 Opening Hours .................................................................................................................................... 16 Medicines Information service - RBH ext. 7803 ................................................................................ 16 Ward pharmacy ................................................................................................................................... 16 Other information................................................................................................................................. 16 Drug representatives ........................................................................................................................... 16 Drug samples ...................................................................................................................................... 16 Adverse drug reaction (ADR) reporting ............................................................................................. 16 Other relevant publications ................................................................................................................. 16 Acknowledgements ............................................................................................................................. 17 0: Emergency treatment of poisoning .............................................................................................. 18 0.1 General Management of Poisoning ............................................................................................... 18 0.2 Activated charcoal .......................................................................................................................... 18 0.3 Availability of Antidotes ................................................................................................................ 19 1: Gastro-intestinal system .............................................................................................................. 20 1.1. Antacids and other drugs for dyspepsia ................................................................................. 20 1.2. Antispasmodics and other drugs altering gut motility .......................................................... 20 NICE approved medicines for specified indications are automatically added to this Formulary 2 Formulary 12 th Edition [v14.3] 1.3. Ulcer healing drugs ................................................................................................................... 21 1.3.1 H2 receptor antagonists ...................................................................................................... 21 1.3.3 Chelates and complexes ..................................................................................................... 21 1.3.4 Prostaglandin analogues .................................................................................................... 21 1.3.5 Proton pump inhibitors ...................................................................................................... 21 1.4. Acute diarrhoea ........................................................................................................................ 21 1.4.2 Antimotility drugs ...................................................................................................................... 21 1.5. Chronic diarrhoeas ................................................................................................................... 22 1.6. Laxatives .................................................................................................................................... 22 1.6.1 Bulk forming drugs .................................................................................................................... 22 1.6.2 Stimulant laxatives ..................................................................................................................... 22 1.6.3 Faecal softener ........................................................................................................................... 22 1.6.4 Osmotic laxatives ....................................................................................................................... 22 1.6.5 Bowel cleansing solutions.......................................................................................................... 23 1.7. Local preparations for anal and rectal disorders .................................................................. 23 1.7.1 Soothing haemorrhoidal preparations ........................................................................................ 23 1.7.3 Rectal sclerosants ...................................................................................................................... 23 1.8. Stoma care ................................................................................................................................. 23 1.9. Drugs affecting intestinal secretions ....................................................................................... 23 1.9.1. Drugs affecting biliary composition & flow ............................................................................. 23 1.9.4 Pancreatin ........................................................................................................................... 23 2: Cardiovascular system .................................................................................................................. 25 2.1 Positive inotropic drugs ............................................................................................................ 25 2.1.1 Cardiac glycosides ..................................................................................................................... 25 2.2 Diuretics ..................................................................................................................................... 25 2.2.1 Thiazides and related diuretics .................................................................................................. 25 2.2.2 Loop diuretics ............................................................................................................................ 25 2.2.3 Potassium-sparing diuretics ......................................................................................................
Recommended publications
  • Cross Reaction Guide

    Cross Reaction Guide

    Individual Reaction Key Methadone(MTD) Phencyclidine(PCP) Amphetamines(AMP) Tricyclic Antidepressants(TCA) Oxycodone(OXY) Barbiturates(BAR) Methamphetamines(MET) Benzodiazepines(BZO) Tramadol(TML) Opiates(OPI, MOP, MOR) Marijuana(THC) Ecstasy(MDMA) Cotinine(COT) Cocaine(COC) Buprenorphine(BUP) Propoxyphene(PPX) Non-reactive Multiple Reaction Key MET and AMP OPI and OXY MDMA and MET MDMA and AMP MET and TCA Generic Name of Compound Trade Name of Compound Results 6-Acetylmorphine N/A Positive: Opiates(OPI, MOP, MOR) Aceta, Acephen, Apacet, Dapacen, Feverall, Acetaminophen (aka Paracetamol) Tylenol, Excedrin (combination), Panadol, Non-reactive Tempra Acetaminophen with Codeine (aka Positive: Opiates(OPI, MOP, MOR) Tylenol 3, Tylenol with Codeine Paracetamol with Codeine) Potential reactants: Dihydrocodeine Acetophenetidin Phenacetin Non-reactive Aspirin, Anadin, Anasin, Bufferin, Caprin, Acetylsalicyclic Acid Disprin, Ecotrin, Empirin, Excedrin Non-reactive (combination) Allobarbital N/A Positive: Barbiturates(BAR) Alphenol N/A Positive: Barbiturates(BAR) Positive: Benzodiazepines(BZO) Potential Alprazolam Xanax reactants: Oxaprozin (Daypro), Sertraline Aluminum Chloride Hexahydrate Drichlor, Anhydrol Forte Non-reactive Alu-Cap, Alisone, Gastrocote, Kolanticon, Aluminum Hydroxide Non-reactive Maalox TC, Mucogel, Pyrogastrone, Topal Alverine Citrate Spasmonal, Spasmonal Fibre Non-reactive Amantadine Symmetrel Positive: Amphetamines(AMP) SpearesMedical.comAminopyrine N/A Non-reactive Elavil, Lentizol, Tryptizol, Triptafen, Triptafen- Amitriptyline
  • In This Section

    In This Section

    Strategic report In this section Chairman’s statement 2 CEO’s review 4 Business overview 6 The global context 8 Our business model 12 Our strategic priorities 14 How we performed 16 Risk management 18 Grow 20 Deliver 32 Simplify 44 Our financial architecture 48 Responsible business 50 Financial review 58 Strategic report Chairman’s statement Chairman’s statement To shareholders The value of the significant changes that have been made in recent years is evidenced in our performance this year “ Since Sir Andrew became It is clear from the following pages that Through the Audit & Risk Committee, we the Group made good progress against oversee the issues and challenges faced by CEO, the company has its strategy in 2013. management, and encourage the creation of an environment in which GSK can achieve The Board believes the business is seeing returned £30 billion its strategic ambitions in a responsible and the benefits of the significant changes the sustainable manner. to shareholders.” management team has driven over recent years to deliver sustainable growth, reduce risk and I have no doubt that commercial success is enhance returns to shareholders. directly linked to operating in a responsible way and which meets the changing expectations of The notably strong performance from the society. In this respect, the company continues R&D organisation in 2013 – with six major to adopt industry-leading positions on a range new product approvals in areas including of issues. respiratory disease, HIV and cancer – is critical to the longer-term prospects of the The announcement of plans during 2013 to Group.
  • University of Groningen Multi-Residue Analysis of Growth Promotors In

    University of Groningen Multi-Residue Analysis of Growth Promotors In

    University of Groningen Multi-residue analysis of growth promotors in food-producing animals Koole, Anneke IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below. Document Version Publisher's PDF, also known as Version of record Publication date: 1998 Link to publication in University of Groningen/UMCG research database Citation for published version (APA): Koole, A. (1998). Multi-residue analysis of growth promotors in food-producing animals. s.n. Copyright Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons). Take-down policy If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim. Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum. Download date: 25-09-2021 APPENDIX 1 OVERVIEW OF RELEVANT SUBSTANCES This appendix consists of two parts. First, substances that are relevant for the research presented in this thesis are given. For each substance CAS number (CAS), molecular weight (MW), bruto formula (formula) and if available UV maxima and alternative names are given. In addition, pKa values for the ß-agonists are listed, if they were available.
  • With Nicotine Replacement Therapies in Smoking Cessation Vol

    With Nicotine Replacement Therapies in Smoking Cessation Vol

    Health Technology Assessment Health Technology Health Technology Assessment 2008; Vol. 12: No. 2 2008; 12: No. 2 Vol. ‘Cut down to quit’ with nicotine replacement therapies in smoking cessation ‘Cut down to quit’ with nicotine replacement therapies in smoking cessation: a systematic review of effectiveness and economic analysis D Wang, M Connock, P Barton, A Fry-Smith, P Aveyard and D Moore Feedback The HTA Programme and the authors would like to know your views about this report. The Correspondence Page on the HTA website (http://www.hta.ac.uk) is a convenient way to publish your comments. If you prefer, you can send your comments to the address below, telling us whether you would like us to transfer them to the website. We look forward to hearing from you. February 2008 The National Coordinating Centre for Health Technology Assessment, Mailpoint 728, Boldrewood, Health Technology Assessment University of Southampton, NHS R&D HTA Programme Southampton, SO16 7PX, UK. HTA Fax: +44 (0) 23 8059 5639 Email: [email protected] www.hta.ac.uk http://www.hta.ac.uk ISSN 1366-5278 HTA How to obtain copies of this and other HTA Programme reports. An electronic version of this publication, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (http://www.hta.ac.uk). A fully searchable CD-ROM is also available (see below). Printed copies of HTA monographs cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our Despatch Agents. Non-UK purchasers will have to pay a small fee for post and packing.
  • PDF (Irish Pharmacist January 2020)

    PDF (Irish Pharmacist January 2020)

    EXCLUSIVE COVERAGE FROM THE RECENT IRISH MEDICATION SAFETY NETWORK ANNUAL CONFERENCE ABOUT-TURN WE LOOK AT WHAT MIGHT BE NEXT FOR PHARMACISTS FOLLOWING THE REVERSAL IN PROPOSED FEE CUTS DUMB AND DUMBER? ARE PHARMACISTS A LITTLE LACKING IN GREY MATTER WHEN IT COMES TO PRICING, ASKS FINTAN MOORE PLUS CLINICAL CONTENT: ASTHMA ❋ COPD ❋ EYE CARE ❋ SMOKING CESSATION TENDER CARE AT Every Change For topical use only. Cleanse and dry the affected area before applying. A copy of the summary of product characteristics is available upon request. The active ingredient in Caldesene Medicated Powder is Calcium Undecylenate 10% w/w, 20g, 55g, 100g pack size. For supply through general sale. PA 126/152/1 PA Holder: Clonmel Healthcare Ltd., Waterford Road, Clonmel, Co. Tipperary. Date Prepared: October 2019. 2019/ADV/CAL/150H NEW TREATS HEARTBURN AND ACID REFLUX. ONE TABLET PER DAY. LASTS 24 HOURS. AVAILABLE IN PACKS OF 7s AND 14s. Marketed by CCF:22656 Date of preparation: (10-19) ABBREVIATED PRESCRIBING INFORMATION Product Name: Emazole Control 20 mg Gastro-Resistant Tablets Composition: Each tablet contains 20 mg esomeprazole (as magnesium dihydrate). Description: Light pink oval film coated tablet. Indication(s): Proton Pump Inhibitor (PPI): Short-term treatment of reflux symptoms (e.g. heartburn and acid regurgitation) in adults. Dosage: Swallow tablets whole with liquid, do not chew or crush. Disperse in half a glass of non-carbonated water if difficulty in swallowing. Stir until tablets disintegrate, drink liquid with pellets immediately or within 15 min, or administer through a gastric tube. Do not chew or crush pellets. Adults: The recommended dose is 20 mg esomeprazole (one tablet) per day.
  • Paul M Mahan Matthews

    Paul M Mahan Matthews

    17 April 2015 PAUL McMAHAN MATTHEWS [email protected] PRIMARY APPOINTMENTS July, 2014- Edmond and Lily Safra Professor of Translational Neuroscience and Therapeutics, Division of Brain Sciences, Department of Medicine, Imperial College London Secured endowment for, and first holder of, new Chair associated with the Divisional Head and posts (Edmond and Lily Safra Scholars) accompanying its foundation. April, 2012- Professor and Head, Division of Brain Sciences, Department of Medicine, Imperial College London Leading a new integration of over 70 academics all clinical and basic neurosciences, neuropsychopharmacology, neurology and mental health within a Division of 200 staff in the Faculty of Medicine with senior management responsibilities across the three academic hospital sites of Imperial College, London. Additional responsibilities as Deputy Director (2008- ) of the Wellcome Trust- GSK Translational Medicine Training Programme, Deputy Director (2011- ) of the BRC Institute for Translational Medicine and Therapeutics, Biomedical Research Centre (BRC) Theme Lead for Neuroscience, co-Director of the Neurotechnology Network and the EPSRC Centre for Doctoral Training in Neurology and Research Advisory Board for the Data Science Institute. July, 2012- February 2014 Vice-President for Integrative Medicines Development, Neurosciences and Medicine Development Lead, GlaxoSmithKline (joint appointment with Imperial College) Leading late phase development programme. Senior advisor to the Head of Neurosciences and China R and D with specific
  • Formulation of Novel Buccal Mucosal Drug Delivery Systems for Nicotine Replacement Therapy (Nrt)

    Formulation of Novel Buccal Mucosal Drug Delivery Systems for Nicotine Replacement Therapy (Nrt)

    FORMULATION OF NOVEL BUCCAL MUCOSAL DRUG DELIVERY SYSTEMS FOR NICOTINE REPLACEMENT THERAPY (NRT). OBINNA CHIKWADO OKEKE A thesis submitted in partial fulfilment of the requirements of the University of Greenwich for the Degree of Doctor of Philosophy January 2017 DECLARATION “I certify that this work has not been accepted in substance for any degree, and is not concurrently being submitted for any purpose. I also declare that this work is the result of my own investigations except where otherwise identified by references and that I have not plagiarised another’s work”. Mr. Obinna C. Okeke (Candidate) Dr J.S. Boateng (First supervisor) i ACKNOWLEDGEMENTS I would like to express my sincere gratitude to my supervisor, Dr Joshua Boateng, for his enormous support, encouragement and general guidance throughout my research. His constant support and encouragement has led me to believe in myself and give out my best. I also appreciate the University of Greenwich for providing the facilities and student support within this period. I would like to acknowledge Dr Ian Slipper for all SEM and XRPD techniques as well as Devyani Amin for HPLC analysis. Thanks to all University staff for supporting my program. I also want to extend my deepest gratitude to my family. Their support and encouragement have led me to the person I am today. I am grateful to Dr Sam and Samantha Owusu-Ware and family for their support. Finally, to all my roommates, officemates, library IT and assistance team, project students under my supervision and fellow postgraduate students, I want to say I big thank you for your support.
  • Malta Medicines List April 08

    Malta Medicines List April 08

    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
  • Anhang Glossar Englisch–Deutsch

    Anhang Glossar Englisch–Deutsch

    Anhang Glossar Englisch–Deutsch Abadie’s sign Abadie-Zeichen, Adenohypophysis Adenohypophyse Dalrymple-Zeichen Adenoma of the thyroid gland Abdominal adiposity Fettverteilung, Schilddrüsenadenom abdominale Adenosine monophosphates Abdominal adipose tissue Fettgewebe, Adenosinmonophosphate viszerales Adenylate cyclase Adenylcyclase A-β-lipoproteinemia (ABL) Adipogenesis Lipogenese A-β-Lipoproteinämie Adipolysis Lipolyse Abnormal lipid metabolism Adiponectin Adiponectin Fettstoffwechselstörungen Adiposity Fettsucht Abnormal lipoprotein metabolism Adiposogenital dystrophia Fröhlich, Fettstoffwechselstörungen Morbus Accelerated hyperthyreoidism Krise, Adipsia Adipsie; Durstverhaltensstö- hyperthyreote rungen Acetatederivatives Essigsäure-Derivate Adolescent goitre Adoleszentenstruma Achard-Thiers syndrome Adrenal adenoma Nebennierenrinde- Achard-Thiers-Syndrom nadenom; Nebennierenrindentumoren, Acid-base balance Säure-Basen- benigne Haushalt Adrenal carcinoma Nebennierenrin- Acid-maltase deficiency Glykogenose, denkarzinom Typ II Adrenal cortex Nebennierenrinde Acidosis Azidose Adrenal cortex autoantibody Acne Akne Nebennierenrinden-Antikörper Acquired adrenogenital syndrome Adrenal gland Nebenniere adrenogenitales Syndrom, erworbenes Adrenal insufficiency Nebennierenrin- Acquired hyperlipoproteinemia deninsuffizienz Hyperlipoproteinämie, sekundäre Adrenal mass Nebennierentumoren Acromegaly Akromegalie Adrenal medulla Nebennierenmark; Acromicria Akromikrie Paraganglion, suprarenales Acropachy Akropachie Adrenal tumor Nebennierenrindentu- Activin
  • Drugs and Related Substances

    Drugs and Related Substances

    CHAPTER 63:04 - DRUGS AND RELATED SUBSTANCES: SUBSIDIARY LEGISLATION (previously "HABIT-FORMING DRUGS") INDEX TO SUBSIDIARY LEGISLATION Declaration of Habit-Forming Drugs Order Drugs and Related Substances Regulations Habit-Forming Drugs (Exempted Preparations) Regulations Habit-Forming Drugs Regulations HABIT-FORMING DRUGS REGULATIONS (under section 12 ) (3rd October, 1922 ) ARRANGEMENT OF REGULATIONS REGULATION 1. Citation 2. Export of habit-forming drugs 3. Form of permit First Schedule - Permit to Export Opium or other Habit-Forming Drugs Second Schedule - Permit to Import or Acquire Habit-Forming Drugs HCN 68, 1922, HCN 87, 1922, HCN 195, 1937, HMC Order 1, 1963, L.N. 84, 1966, S.I. 12, 1977. 1. Citation These Regulations may be cited as the Habit-forming Drugs Regulations. 2. Export of habit-forming drugs Any duly registered medical practitioner, dentist or chemist and druggist, and any duly qualified veterinary surgeon who is desirous of exporting from Botswana any habit-forming drug as defined in the Act (other than prepared opium as defined in the Act), shall- (a) furnish to the Minister a certificate from the government or administration of the importing country to the effect that such government or administration is satisfied that the consignment of such habit-forming drug is required solely for medicinal or scientific purposes, and that it approves of its importation; (b) obtain from the Minister a permit under section 4(4) of the Act in the form in the First Schedule hereto. 3. Form of permit The form of permit to import or acquire habit-forming drugs as provided for in section 5(1) of the Act shall be as contained in the Second Schedule hereto.
  • TOX/See Drug Screen Test

    TOX/See Drug Screen Test

    LB0004363 TM TOX/See Drug Screen Test TOX/See TM Cross-Reactivity Table by Trade Name This document is for informational use only; it is not intended to replace confirmative testing. TOX/See TM Drug Screen Test CONCENTRATION COMPOUND (Generic Name) COMPOUND (Trade Name) RESULTS FOR POSITIVE Abacavir Ziagen Non-reactive ,, Acamprosate Campral Non-reactive Acetaminophen (See also Paracetamol) Aceta Non-reactive Acetaminophen (See also Paracetamol) Acephen Non-reactive Acetaminophen (See also Paracetamol) Apacet Non-reactive Acetaminophen (See also Paracetamol) Dapacen Non-reactive Acetaminophen (See also Paracetamol) Feverall Non-reactive ' ' ·,, Acetaminophen (See also Paracetamol) Tylenol Non-reactive ' Acetaminophen (See also Paracetamol) Excedrin (combination) Non-reactive ,, ' :· Acetaminophen (See also Paracetamol) Panadol Non-reactive f.,1· ··<!:•:•· •: '; ,.; .. ·,. Acetaminophen (See also Paracetamol) Tempra Non-reactive ):., '' ·.·~- with Codeine Positive for Opiates MOR= 300 ng/ml Acetaminophen Tylenol3 l<see also Paracetamol with codeine) I(OPI , MOR) OPI = 2,000 ng/ml Positive for Opiates MOR= 300 ng/ml Acetaminophen with Codeine Tylenol with codeine l(see also Paracetamol with codeine) I<OPI, MOR) OPI = 2,000 ng/ml Acetic Acid Ethanoic Acid Non-reactive ~:~w-~{'"·.:;; .. Acetophenetidin Phenacetin Non-reactive f<:;~·§;~j.,;:; ~::: Acetylsalicyclic acid Aspirin Non-reactive 'f.~;k;,';J~:,·; ';~rr. Acetylsalicyclic acid Anadin Non-reactive ' ;': ' f.i~:j~ :;f.: ~. '• Acetylsalicyclic acid Ana sin Non-reactive 1 ;.;:·.\~~·~:;:~,
  • OUH Formulary Approved for Use in Breast Surgery

    OUH Formulary Approved for Use in Breast Surgery

    Oxford University Hospitals NHS Foundation Trust Formulary FORMULARY (Y): the medicine can be used as per its licence. RESTRICTED FORMULARY (R): the medicine can be used as per the agreed restriction. NON-FORMULARY (NF): the medicine is not on the formulary and should not be used unless exceptional approval has been obtained from MMTC. UNLICENSED MEDICINE – RESTRICTED FORMULARY (UNR): the medicine is unlicensed and can be used as per the agreed restriction. SPECIAL MEDICINE – RESTRICTED FORMULARY (SR): the medicine is a “special” (unlicensed) and can be used as per the agreed restriction. EXTEMPORANEOUS PREPARATION – RESTRICTED FORMULARY (EXTR): the extemporaneous preparation (unlicensed) can be prepared and used as per the agreed restriction. UNLICENSED MEDICINE – NON-FORMULARY (UNNF): the medicine is unlicensed and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. SPECIAL MEDICINE – NON-FORMULARY (SNF): the medicine is a “special” (unlicensed) and is not on the formulary. It should not be used unless exceptional approval has been obtained from MMTC. EXTEMPORANEOUS PREPARATION – NON-FORMULARY (EXTNF): the extemporaneous preparation (unlicensed) cannot be prepared and used unless exceptional approval has been obtained from MMTC. CLINICAL TRIALS (C): the medicine is clinical trial material and is not for clinical use. NICE TECHNOLOGY APPRAISAL (NICETA): the medicine has received a positive appraisal from NICE. It will be available on the formulary from the day the Technology Appraisal is published. Prescribers who wish to treat patients who meet NICE criteria, will have access to these medicines from this date. However, these medicines will not be part of routine practice until a NICE TA Implementation Plan has been presented and approved by MMTC (when the drug will be given a Restricted formulary status).